Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Multiple sclerosis.
- A. Compston, A. Coles
- Medicine
- Lancet
- 2002
Multiple sclerosis is the prototype inflammatory autoimmune disorder of the central nervous system and, with a lifetime risk of one in 400, potentially the most common cause of neurological… Expand
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- J. Cohen, A. Coles, D. Arnold, C. Confavreux, F. T. C. I. investigators
- Medicine
- The Lancet
- 24 November 2012
BACKGROUND
The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess… Expand
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- A. Coles, Cary L Twyman, D. Arnold, J. Cohen, F. T. C. I. investigators
- Medicine
- The Lancet
- 24 November 2012
BACKGROUND
The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety… Expand
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
- A. Coles, D. Compston, +5 authors P. K. Tandon
- Medicine
- The New England journal of medicine
- 23 October 2008
BACKGROUND
Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis.
METHODS
In this phase 2,… Expand
The window of therapeutic opportunity in multiple sclerosis
- A. Coles, A. Cox, +8 authors D. Compston
- Medicine
- Journal of Neurology
- 2005
AbstractFrom 1991–2002, we
treated 58 patients with multiple
sclerosis (MS) using the humanised
monoclonal antibody, Campath–1H, which causes prolonged T
lymphocyte depletion. Clinical and
surrogate… Expand
Multiple sclerosis
- A. Compston, A. Coles
- Medicine
- The Lancet
- 31 October 2008
Multiple sclerosis is primarily an inflammatory disorder of the brain and spinal cord in which focal lymphocytic infiltration leads to damage of myelin and axons. Initially, inflammation is transient… Expand
Disease-relevant autoantibodies in first episode schizophrenia
Dear Sirs,
Schizophrenia is a common, heterogenous and complex disorder with unknown aetiology [1]. There is established evidence for N-methyl-d-aspartate receptor (NMDAR) hypofunction [2] as a… Expand
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
- O. Tuohy, L. Costelloe, +11 authors A. Coles
- Medicine
- Journal of Neurology, Neurosurgery & Psychiatry
- 21 May 2014
Objectives Alemtuzumab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe, which in phase II and III studies demonstrated superior efficacy over… Expand
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
- S. Thompson, J. Jones, A. Cox, D. Compston, A. Coles
- Medicine
- Journal of Clinical Immunology
- 2009
IntroductionTreatment with alemtuzumab is highly effective in relapsing–remitting multiple sclerosis; however, 30% of patients develop autoimmunity. Alemtuzumab (previously called Campath 1-H)… Expand
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
- J. Jones, S. Thompson, +8 authors A. Coles
- Biology, Medicine
- Proceedings of the National Academy of Sciences
- 26 November 2013
Significance This paper identifies the mechanism by which patients with multiple sclerosis develop secondary autoimmunity after treatment with the lymphocyte-depleting humanized monoclonal antibody… Expand
...
1
2
3
4
5
...